DCVMN Annual General Meeting (Virtual): Vaccines, a healthy future
3 November 2020 – 5 November 2020
Agenda of the 21st annual meeting
Speakers book 21st annual meeting
PRESENTATIONS
General Meeting presentation materials available for download (PDF):
Tuesday, 3rd November 2020
Video: Merck – Re-imagining vaccine manufacturing
- Update on NEW VVMs in support of SARS-COV2 vaccine delivery – Temptime
- Re-imagining vaccine manufacturing – Merck
- Aseptic blow-fill-seal fill/finish technology and vaccines – Rommelag
- Tofflon Best Practice for Human Vaccine Manufacturing – Tofflon
- Biozeen approach to steering covid – 19 vaccine manufacturing dynamics – Biozeen
- Considerations for adapting existing facilities to changing vaccine development demands – Bioengineering
- Vaccine Production with GEA pharma separators – GEA
Wednesday, 4rd November 2020
- The ACT Accelerator – The plan, progress & the challenges
- The COVAX Facility and the AMC – GAVI
- COVID vaccines development & manufacturing – CEPI
- UNICEF Procurement for COVID-19 Vaccines – UNICEF
- VIPS: Next steps post prioritisation – VIPS
- Imperial Future Vaccine Manufacturing Research Hub – Imperial College
- Data, decision-making and development – CHAI
- The PAHO COVID-19 Response – PAHO
- Pandemic Response: the critical role of DCVMs – Gates Foundation
Thursday, 5rd November 2020
- IVI’s collaborations to develop new vaccines – IVI
- Regulatory challenges for COVID-19 Vaccine Development – CEPI
- COVID-19 Vaccine: Clinical Trials and Tribulations – Bharat Biotech
- Cross-continent Vaccine Collaboration against COVID-19 – SINOVAC
- Covid-19: Vaccine activities – Biological E.
- Covid-19 Vaccine R&D and CNBG’s Product Portfolio – CNBG
- Manufacture of Covid-19 Vaccine Overview and Challenges – Serum Institute of India
- Regulatory alignment and authorization of vaccines under EUL/PQ – WHO
- Harmonization of regulatory approaches in African countries – WHO efforts – WHO
- 3Rs Improvement of legacy vaccines release testing – Istituto Superiore di Sanità
- Closing Remarks – DCVMN
